Journal of Oncology / 2010 / Article / Tab 1

Review Article

Progress on Antiangiogenic Therapy for Patients with Malignant Glioma

Table 1

Examples of antiangiogenic agents in clinical trial for patients with high grade glioma.


ABT-510Thrombospondin-1 mimetic peptideCD36 receptor
AMG 102Monoclonal antibodyHGF/SF
AfliberceptSoluble decoy receptorVEGF-A,B, PlGF
BevacizumabMonoclonal antibodyVEGF-A
BrivanibTyrosine kinase inhibitorFGFR, VEGFR2
CediranibTyrosine kinase inhibitorVEGFR1–3, PDGFRβ, c-Kit
CilengitideRGD synthetic peptideIntegrins αvβ3, αvβ5
CT-322Fibronectin (adnectin)-based inhibitorVEGFR1–3
DasatinibTyrosine kinase inhibitorPDGFRβ, Src, BCR-ABL, c-Kit, EphA2
ImatinibTyrosine kinase inhibitorPDGFRβ, BCR-ABL, c-Kit
LenalidomideImmunomodulatory and anti-inflammatoryFGF pathway
Pazopanib (GW786034)Tyrosine kinase inhibitorVEGFR1–3, PDGFRβ, c-Kit
SorafenibTyrosine kinase inhibitorVEGFR2,3, BRAF, PDGFRβ, c-Kit, Ras, p38α
SunitinibTyrosine kinase inhibitorVEGFR2, PDGFRβ, Flt3, c-Kit
Tandutinib (MLN518)Tyrosine kinase inhibitorPDGFRβ, Flt3, c-Kit
Vandetanib (ZD6474)Tyrosine kinase inhibitorVEGFR2, EGFR, RET
Vatalanib (PTK787)Tyrosine kinase inhibitorVEGFR1–3, PDGFRβ, c-Kit
XL-184Tyrosine kinase inhibitorVEGFR2, Met, RET, c-Kit, Flt3, Tie-2

A more complete listing of anti-angiogenic agents in clinical trials for patients with high grade gliomas can be found at the National Institutes of Health website when searching for “glioma, brain cancer, glioblastoma, and angiogenesis”.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.